Open this photo in gallery:
Pfizer notified Health Canada on Nov. 3 that it would stop supplying Premarin cream and tablets.Cole Burston/The Globe and Mail
Menopause specialists are concerned about how Canadian patients will be affected by Pfizer’s recent decision to stop supplying a vaginal cream and oral estrogen tablets in Canada, while continuing to offer them in the U.S.
Physicians say they fear patients will have to contend with the ramifications of Pfizer’s decision, made public last week, to discontinue Premarin cream and tablets in Canada, prescribed to those navigating menopause symptoms. Existing inventory is expected to last until next year.
Premarin was first developed and approved in Canada in 1941 and Pfizer manufactures the global supply of the active ingredient in Brandon, Man. It comes from the urine of pregnant mares in Manitoba and Saskatchewan.
Pfizer first notified Health Canada on Nov. 3 that it would stop supplying Premarin products, according to a federal drug-shortage database. The cream is being discontinued immediately and pills will be available while inventory lasts, potentially until next June, according to notices on the database.
Pfizer said Premarin products were “commercially unsustainable” in Canada.
The company “considered a range of factors, including manufacturing and supply costs, the pricing and reimbursement environment, and the ability to maintain sustainable supply over the longer term,” said Sophie Morin, a spokesperson for Pfizer Canada, in an e-mail.
The federal database shows the Premarin cream has been in shortage four times since the beginning of 2025.
In Depth: Public menopause care is scarce, and private care is costly. Why Canadians pay either way
In the U.S., demand has grown for menopause hormone therapy, including after the Food and Drug Administration initiated the removal of long-standing safety warnings on the treatments last November. Health Canada has not removed similar warnings on products here.
Demand for the products is also on the rise in Canada. In September, a report from Manulife Canada about its group benefits showed a 228-per-cent increase in hormone-replacement therapy claims over five years among women 45 to 54.
Canadian obstetrician-gynecologist Jen Gunter wrote Wednesday on her blog that Pfizer’s decision should concern all Canadians.
“This isn’t just about Premarin,” she wrote. “Every Canadian who cares about access to medications need to be engaged and speak up.”
In its cream form, Premarin allows for estrogen to be applied directly to vaginal tissue. It is used to treat atrophic vaginitis, including drying of the vaginal walls, as well as shrinkage of the skin of the vagina and vulva. It can also be used to address dyspareunia, which is pain or discomfort during intercourse.
While there are some alternatives available, Dr. Gunter wrote that Premarin may be better for some patients in terms of side effects and efficacy.
Also, physicians say stopping certain treatments can lead to a rebound of symptoms, such as hot flashes and vaginal irritation, and can set back patients in their menopause care.
A tube of Premarin cream in Canada typically retails for around $50 because of federal drug rules. By comparison, it retails for around $400 to $500 in the United States. Some patients can access the cream for a lower price if they have insurance coverage.
What the menopause gap in the labour force is costing Canada
Rithvika Ramesh, a family physician in Toronto, said the discontinuation affects some of her patients.
It is the only vaginal estrogen cream covered under the Ontario Drug Benefit program, she said. The drug funding plan covers the cost of certain medications for eligible residents.
She said the vaginal cream has long been an important treatment option for patients experiencing genitourinary symptoms of menopause. Additionally, she said it is used to help prevent recurrent urinary tract infections.
Dr. Ramesh said for older adults in particular, preventing UTIs can be life-saving, noting that a seemingly uncomplicated infection can progress to kidney infection, hospitalization and, sometimes, sepsis.
Sepsis is when the body’s immune system reacts in an extreme way to an infection and it can cause organs to shut down and in some cases, lead to death.
“Access to effective vaginal estrogen is not simply a matter of quality of life but an important component of preventative health care,” Dr. Ramesh said.
How menopause symptoms affects women and the economy, according to our experts
Lily Barnes, a spokesperson for Ontario Health Minister Sylvia Jones, said vaginal estrogen products identified by the Canadian Menopause Society, including a vaginal ring, tablet and inserts, are still covered on the provincial drug formulary.
The Canadian Pharmacists Association has developed a resource for health care providers to manage supply changes, she added.
Dr. Ramesh said those who rely on the product may face additional out-of-pocket costs and could have to transition to a product that doesn’t adequately align with their symptoms, preferences and needs.
Dr. Gunter also voiced concerns about how the discontinuation will affect patients and wants the federal government to get involved in the matter.
“The federal government oversees drug approvals and international trade policies,” Dr. Gunter wrote. “It is legitimate to ask our elected officials and members of the Senate to find out why this is happening.”
A spokesperson for federal Health Minister Marjorie Michel’s office said that Health Canada is assessing the effects of the discontinuation of Premarin on menopause hormone-therapy supply in Canada, and will act as needed to minimize the impact of shortages.